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ABSTRACT Human adenoviral serotype 5 (HAdV-5) vectors have predominantly he-
patic tropism when delivered intravascularly, resulting in immune activation and tox-
icity. Coagulation factor X (FX) binding to HAdV-5 mediates liver transduction and
provides protection from virion neutralization in mice. FX is dispensable for liver
transduction in mice lacking IgM antibodies or complement, suggesting that alterna-
tive transduction pathways exist. To identify novel factor(s) mediating HAdV-5 FX-
independent entry, we investigated HAdV-5 transduction in vitro in the presence of
serum from immunocompetent C57BL/6 or immunocompromised mice lacking IgM
antibodies (Rag 2/ and NOD-scid-gamma [NSG]). Sera from all three mouse strains
enhanced HAdV-5 transduction of A549 cells. While inhibition of HAdV-5–FX in-
teraction with FX-binding protein (X-bp) inhibited transduction in the presence
of C57BL/6 serum, it had negligible effect on the enhanced transduction observed in
the presence of Rag 2/ or NSG serum. Rag 2/ serum also enhanced transduc-
tion of the FX binding-deﬁcient HAdV-5HVR5*HVR7*E451Q (AdT*). Interestingly, Rag
2/ serum enhanced HAdV-5 transduction in a FX-independent manner in CHO-
CAR and SKOV3-CAR cells (CHO or SKOV3 cells transfected to stably express human
coxsackievirus and adenovirus receptor [CAR]). Additionally, blockade of CAR with
soluble HAdV-5 ﬁber knob inhibited mouse serum-enhanced transduction in A549
cells, suggesting a potential role for CAR. Transduction of HAdV-5 KO1 and HAdV-5/
F35 (CAR binding deﬁcient) in the presence of Rag 2/ serum was equivalent to
that of HAdV-5, indicating that direct interaction between HAdV-5 and CAR is not re-
quired. These data suggest that FX may protect HAdV-5 from neutralization but has
minimal contribution to HAdV-5 transduction in the presence of immunocompromised
mouse serum. Alternatively, transduction occurs via an unidentiﬁed mouse serum pro-
tein capable of bridging HAdV-5 to CAR.
IMPORTANCE The intravascular administration of HAdV-5 vectors can result in acute
liver toxicity, transaminitis, thrombocytopenia, and injury to the vascular endothe-
lium, illustrating challenges yet to overcome for HAdV-5-mediated systemic gene
therapy. The ﬁnding that CAR and potentially an unidentiﬁed factor present in
mouse serum might be important mediators of HAdV-5 transduction highlights that
a better understanding of the complex biology deﬁning the interplay between ade-
novirus immune recognition and cellular uptake mechanisms is still required. These
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ﬁndings are important to inform future optimization and development of HAdV-5-
based adenoviral vectors for gene therapy.
KEYWORDS adenovirus, CAR, receptor, serum, tropism
Vectors based on human adenoviral serotype 5 (HAdV-5) are promising for genetherapy and vaccination applications. However, although HAdV-5-based vectors
are widely used in clinical trials (http://www.wiley.com//legacy/wileychi/genmed/
clinical/), their use for gene therapy following intravascular delivery is limited by high
hepatic tropism, which leads to activation of antiviral immune responses and toxic side
effects (1–4). While the classical in vitro pathway for HAdV-5 transduction is primarily via
the capsid ﬁber protein binding to the coxsackievirus and adenovirus receptor (CAR)
and subsequent internalization via the capsid penton base engaging v3,5 integrins
(5–8), the in vivo entry pathway is still being elucidated in detail.
Previous studies have reported host cell receptors and factors that dictate HAdV-5
tropism. Coagulation factor X (FX) was identiﬁed as the key factor mediating HAdV-5
liver transduction (9). FX binds to the capsid hexon proteins in 1:1 stoichiometry at
nanomolar afﬁnity and bridges HAdV-5 to heparan sulfate proteoglycan (HSPG) on
hepatocytes leading to hepatic transduction (9–11). FX binds to the HAdV-5 hexon
hypervariable regions (HVRs) through its -carboxyl glutamic acid (GLA) domain while
also binding to the N- and O-linked sulfate groups of HSPGs via the serine protease (SP)
domain (10–15). Genetic engineering of HAdV-5 to ablate the key residues in the hexon
HVRs that interact with FX greatly diminished liver transduction (12, 16), highlighting
the key role this pathway plays in mediating hepatic gene delivery. More recently, an
alternative role for the HAdV-5–FX interaction was deﬁned, which involves FX capsid
coating or “shielding,” resulting in protection of the virus from neutralization or
“immune attack” (17–19). Adenoviral neutralization was shown to be mediated by
natural immunoglobulin M (IgM) antibodies and the complement system present in
mouse serum, which block binding of virions to host cells and thus prevent transduc-
tion (17). In particular, FX was shown to prevent binding of human IgM antibodies to
virions (19) and activation of mouse C3 (complement component 3) convertase and
subsequent covalent modiﬁcation of virions with C3 (17). It was also demonstrated that
hepatic tropism of HAdV-5 did not require HAdV-5–FX interaction in immunocompro-
mised mice lacking IgM antibodies, complement protein C1q, or complement compo-
nent 4 (C4) (17). Furthermore, a recent study reported that while HAdV-5 uses the FX-
and HSPG-mediated transduction pathway in primary hepatocytes in vitro, in vivo liver
transduction was not signiﬁcantly reduced in mice lacking Ext1, an enzyme required for
heparan sulfate (HS) biosynthesis (20). Thus, these recent reports suggest the involve-
ment of other unidentiﬁed alternative transduction mechanisms for HAdV-5 when the
FX-mediated pathway is unavailable. These alternative transduction pathways may be
mediated directly via HAdV-5 engaging with cellular receptors or by bridging to
intermediate molecules.
Many studies have attempted to identify speciﬁc cell surface receptors mediating
HAdV-5 tropism. Direct interactions between adenoviral vectors and heparan sulfate
glycosaminoglycan (HS-GAG) have demonstrated that HS-GAG can facilitate HAdV-5
binding and infectivity of A549 and HeLa cells in vitro (21, 22). However, genetic
mutations to ablate adenoviral binding to HSPG (23–25) or the use of mouse models
that lack heparan sulfate (20) failed to achieve liver detargeting. Although other studies
have shown that mutation of the ﬁber shaft to ablate a putative HSPG-interacting motif
could reduce liver transduction (26, 27) and cell transduction in vitro (25), it is now
widely believed that these effects are possibly due to alterations in the ﬁber structure,
conferring rigidity and thus hampering simultaneous binding to CAR and v3,5
integrins and affecting trafﬁcking of virions, rather than modulating direct binding to
HSPG (25, 28). Moreover, ablating the ability of HAdV-5 to interact with CAR or v3,5
integrins has for the most part failed to achieve efﬁcient liver detargeting (20, 23, 26,
27, 29–34). However, in these studies, genetic mutations in individual capsid proteins
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(ﬁber and penton base) were assessed, thus not addressing the possibility that HAdV-5
may use as yet unidentiﬁed circulating blood factors to interact with cell surface
receptors via a bridging mechanism.
Indeed, HAdV-5 has been previously reported to interact with several circulating
blood proteins such as C4-binding protein (C4BP) (35), coagulation factor VII (FVII) (9),
coagulation factor IX (FIX) (9, 10, 35), and protein C (PC) (9, 10). Despite FVII being able
to bind to HAdV-5 and containing a heparin-binding exosite (36, 37), it may be unable
to interact with HSPG when forming a complex with HAdV-5 due to the formation of
dimers between the FVII SP domains (37). FIX also binds to HAdV-5 (10), and like FVII,
it has a heparin-binding exosite (38, 39). However, no evidence of FIX dimer formation
has yet been described, suggesting FIX might potentially bridge HAdV-5 to HS for cell
transduction. Indeed, FIX has been reported to enhance binding to and infection of
epithelial cells with HAdV-18 (40) and with HAdV-31 through HS-GAG (41). Furthermore,
FIX enhanced HAdV-5-mediated transduction of mouse hepatocytes and Kupffer cells
in vitro and in vivo and human hepatocytes in vitro (35). C4BP has also been reported
to confer CAR-independent adenoviral transduction of primary human hepatocytes in
vitro (35), while PC was shown to mediate HepG2 hepatocyte transduction (9).
To investigate possible HAdV-5 transduction pathways involving interactions with
bridging molecules that may be relevant in vivo, in the present study, we evaluated
HAdV-5 transduction in vitro in the presence or absence of mouse serum from immu-
nocompetent or immunocompromised strains. Our ﬁndings suggest that HAdV-5 vec-
tors exposed to mouse serum are able to use different mechanisms of cell entry. In
addition to the well-known FX-mediated pathway of HAdV-5 cell entry, we report use
of a FX-independent and CAR-mediated mechanism for HAdV-5 transduction in vitro in
the presence of mouse serum, which is independent of ﬁber knob interaction with CAR.
RESULTS
Serum from immunocompromised mice enhances HAdV-5 transduction in vitro
via a FX-independent mechanism. To study the effect of mouse serum on adenoviral
transduction of cells in vitro, transduction assays were performed in A549 cells using
HAdV-5 -galactosidase, with the addition of serum from immunocompetent or im-
munocompromised mice. As expected, adenoviral transduction occurred at low levels
in the presence of serum-free media alone (Fig. 1A). Immunocompetent C57BL/6 serum
signiﬁcantly enhanced HAdV-5 transduction by approximately 2.4-fold (Fig. 1A), high-
lighting the presence of a factor(s) in serum that enhances HAdV-5 transduction.
Preincubation of C57BL/6 serum with FX-binding protein (X-bp), a molecule that
suppresses HAdV-5–FX interactions by speciﬁcally binding to the FX GLA domain (42),
substantially inhibited transduction (Fig. 1A). These data are in agreement with previ-
ous reports showing that incubation of HAdV-5 with C57BL/6 serum in the absence of
HAdV-5–FX binding results in loss of transduction and is consistent with the hypothesis
of natural IgM antibodies and complement-mediated adenovirus neutralization inhib-
iting HAdV-5 binding to host cells (17, 18).
Next, to assess whether FX is involved in HAdV-5 transduction of cells in vitro in the
absence of adenovirus neutralization, transduction assays were performed with serum
from immunocompromised Rag 2/ mice. These mice are unable to differentiate B
and T lymphocytes to a mature state, thus lacking IgM antibodies (43, 44), one of the
mediators of HAdV-5 neutralization in vitro in the absence of HAdV-5–FX binding (17).
Similar to observations with C57BL/6 serum, Rag 2/ serum signiﬁcantly enhanced
HAdV-5 transduction by approximately 3.5-fold (Fig. 1A). In contrast to C57BL/6 serum,
Rag 2/ serum preincubated with X-bp did not inhibit HAdV-5 transduction (Fig. 1A),
showing that Rag 2/ serum was unable to neutralize HAdV-5. Preincubation of Rag
2/ serum with X-bp resulted in a small decrease in HAdV-5 transduction compared
to transduction in the absence of X-bp (Fig. 1A), indicating that FX may only partially
contribute to the enhanced cell transduction observed with Rag 2/ serum. Impor-
tantly, this reduction was substantially less than that observed in the presence of
C57BL/6 mouse serum and X-bp (Fig. 1A). To dismiss possible individual mouse
Novel Role for CAR in HAdV-5 Transduction Journal of Virology
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strain-speciﬁc effects, these results were conﬁrmed using serum from NOD-scid-gamma
(NSG) mice, another immunocompromised mouse strain (Fig. 1A). These mice are
not able to produce mature B or T lymphocytes, are defective in dendritic cell and
macrophage cytokine production and hemolytic complement protein 5 (C5), and have
extremely low natural killer (NK) cell cytotoxic activity (45). NSG mice were also chosen
due to their lack of IgM antibody production (46). The transduction proﬁle for HAdV-5
in the presence of NSG serum matched that of Rag 2/ serum.
To further conﬁrm HAdV-5 transduction in the presence of immunocompromised
mouse serum was via a FX-independent mechanism, the FX binding-deﬁcient AdT* (12)
was used in comparison to HAdV-5. Lack of sensitivity to FX was conﬁrmed for AdT* by
assessing cell transduction in the presence or absence of FX in A549 or SKOV3 cells,
which express high or low levels of CAR on the plasma membrane, respectively. While
FX signiﬁcantly enhanced HAdV-5 transduction in both cell lines, transduction enhance-
ment for AdT* was negligible compared to that of HAdV-5 (Fig. 1B and data not shown).
Transduction assays were then performed with AdT* in the presence of immunocom-
petent C57BL/6 or immunocompromised Rag 2/ serum. As expected, C57BL/6 serum
inhibited AdT* transduction both in the presence or absence of X-bp (Fig. 1C), con-
ﬁrming again the adenovirus neutralization properties of immunocompetent C57BL/6
serum in the absence of FX binding. In contrast, Rag 2/ serum enhanced AdT*
transduction, and X-bp had no effect on this enhancement (Fig. 1C). These data
therefore conﬁrm that HAdV-5 predominantly uses a FX-independent pathway for
transduction in the presence of immunocompromised Rag 2/ serum.
To investigate whether a FX-independent mechanism of HAdV-5 transduction is also
observed in the presence of immunocompetent C57BL/6 serum, HAdV-5 transduction
of A549 cells was assessed in the presence of C57BL/6 serum that had been preincu-
bated at 56°C for 30 min to inactivate the complement system and thus inhibit
adenovirus neutralization (17). Immunocompromised Rag 2/ serum was used as a
nonneutralizing control serum. As expected, C57BL/6 and Rag 2/ serum not sub-
jected to heat treatment signiﬁcantly enhanced HAdV-5 transduction (2.2-fold and
FIG 1 Effect of mouse serum or coagulation factor X (FX) on adenoviral transduction. (A and C to F) HAdV-5 or AdT* (FX binding-deﬁcient) (2  1010 vp/ml)
was incubated for 30 min at 37°C with serum-free (SF) media, 90% C57BL/6, Rag 2/, or NSG serum in the presence or absence of X-bp (40 g/ml) (A and
C to E) or with human FX (hFX) (10 g/ml) in SF media (F). When indicated, hFX or mouse serum was preincubated at 56°C for 30 min before the addition of
X-bp (D to F). Adenovirus suspensions were added to A549 cells (MOI of 1,000 vp/cell) and incubated at 37°C for 2 h. The medium was then replaced with media
containing 2% FCS, and the cells were incubated for another 20 h. (B) A549 cells were incubated with HAdV-5 or AdT* (MOI, 1,000 vp/cell) at 37°C for 3 h in
the presence () or absence () of hFX (10 g/ml), the medium was replaced with 10% FCS-containing media, and the cells were incubated for further 48 h.
-Galactosidase expression levels were quantiﬁed as relative light units (RLU) and normalized to the total milligrams of protein (A to F). There were four technical
replicates per condition (B), pooled data from seven (C57BL/6), six (Rag 2/), or three (NSG) mice (A and C), or three (D to F) independent experiments with
four replicates per condition. Values are shown as a percentage of the SF-medium-alone condition and expressed as the mean of values (B) or of the normalized
values per experiment (A and C to F) plus standard error of the mean (SEM) (error bar). Repeated-measures ANOVA and posthoc Tukey’s range test (A and C
to F) or unpaired Student’s t test (B) were applied. Values that are signiﬁcantly different are indicated as follows: *, P  0.05 versus matched controls; $, P 
0.05 versus serum; #, P  0.05 versus serum plus X-bp.
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3.3-fold, respectively), and addition of X-bp to C57BL/6 serum inhibited HAdV-5 trans-
duction in contrast to Rag 2/ serum (Fig. 1D and E). Heat-treated C57BL/6 serum
preincubated with X-bp failed to inhibit HAdV-5 transduction (Fig. 1D), similar to that
observed with heat-treated Rag 2/ serum in the presence of X-bp (Fig. 1E), indicating
that adenovirus neutralization was successfully inhibited by heat. Interestingly, expo-
sure of C57BL/6 or Rag 2/ serum to heat inhibited the transduction-enhancing
properties of both sera (Fig. 1D and E), suggesting a role for heat-labile factors in in vitro
neutralization and transduction of adenoviral vectors. To conﬁrm that FX is heat labile,
HAdV-5 transduction of A549 cells was assessed in the presence of heat-treated hFX.
While hFX enhanced HAdV-5 transduction by 2.9-fold, heat-treated hFX failed to
enhance HAdV-5 transduction (Fig. 1F). These data suggest that both FX-dependent
and -independent mechanisms of HAdV-5 transduction in the presence of mouse
serum are mediated by heat-labile factors.
Immunocompromised mouse serum enhances HAdV-5 transduction in cell
lines expressing high levels of CAR in a FX-independent manner. We next inves-
tigated the role of CAR as a possible cellular receptor for the observed mouse
serum-enhanced HAdV-5 transduction of cells in vitro. HAdV-5 transduction assays were
performed in the presence of Rag 2/ serum and X-bp in HeLa and HepG2 cell lines,
which express CAR at high levels on the plasma membrane, similar to A549 cells (Fig.
2A). For both HeLa and HepG2 cells, HAdV-5 transduction was enhanced by Rag 2/
serum, and addition of X-bp to Rag 2/ serum had little effect on transduction
enhancement (Fig. 2B), equivalent to that observed earlier for A549 cells. These data
indicate that a FX-independent pathway for HAdV-5 transduction is also present in
other high-CAR-expressing cell lines in the presence of Rag 2/ serum, suggesting a
possible role for CAR in the observed paradigm.
Immunocompetent and immunocompromised mouse sera enhance HAdV-5
transduction in vitro in a CAR-dependent manner. To further assess the role of CAR
FIG 2 Adenoviral transduction in the presence of immunocompromised mouse serum in different cell lines
expressing high levels of CAR. (A) CAR expression levels on cell plasma membrane were tested by ﬂow cytometry
in A549, HeLa, and HepG2 cells. CAR-positive cells are expressed as a percentage of the parental population and
the mean of technical triplicates SEM. Representative data are shown. (B) HAdV-5 (2 1010 vp/ml) was incubated
for 30 min at 37°C with serum-free (SF) media or 90% Rag 2/ serum in the presence or absence of X-bp (40
g/ml). Adenovirus suspensions were added to HeLa or HepG2 cells (MOI, 1,000 vp/cell) and incubated at 37°C for
2 h. Then, the medium was replaced with media containing 2% FCS, and the cells were incubated for an additional
20 h. -Galactosidase expression levels were quantiﬁed as relative light units (RLU) and normalized to the total
milligrams of protein. The data represent pooled values from six (HeLa cells) or three (HepG2 cells) independent
experiments with four replicates per condition. Values are shown as a percentage of the SF-medium-alone
condition and expressed as the mean of the normalized values per experiment plus SEM. Repeated-measures
ANOVA and posthoc Tukey’s range test were applied. *, P 0.05 versus matched controls; $, P 0.05 versus serum.
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in HAdV-5 transduction in the presence of immunocompromised mouse serum, trans-
duction experiments were performed in CHO-K1 control cells and CHO cells stably
expressing human CAR (hCAR) (CHO-CAR) (5) (Fig. 3A) in the presence of Rag 2/
serum and X-bp. Transduction of CAR-negative CHO-K1 cells with HAdV-5 was negli-
gible (Fig. 3B), in agreement with previous reports (47), and Rag 2/ serum did not
enhance transduction (Fig. 3B), suggesting that mouse FX (mFX) is unable to mediate
transduction in CHO-K1 cells, as reported previously (48). Interestingly, CHO-CAR cells
showed a transduction pattern (Fig. 3C) similar to that observed in A549 cells (Fig. 1A
and C). The transduction enhancement for HAdV-5 in the presence of Rag 2/ serum
was approximately threefold and unaffected by preincubation with X-bp (Fig. 3C),
indicating that HAdV-5 transduction of CHO-CAR cells was not dependent on FX. In
addition, AdT* transduction was efﬁciently enhanced by Rag 2/ serum in CHO-CAR
cells (Fig. 3C). These data suggest that a FX-independent and CAR-mediated mecha-
nism may be responsible for HAdV-5 transduction of CHO-CAR cells in the presence of
Rag 2/ serum.
FIG 3 Adenoviral transduction in the presence of immunocompromised mouse serum in different cell lines engineered to express CAR. (A and D) CAR
expression levels on cell plasma membrane were tested by ﬂow cytometry in CHO-K1 and CHO-CAR cells (A) and SKOV3 and SKOV3-CAR cells (D). CAR-positive
cells are expressed as a percentage of the parental population and the mean of technical triplicates  SEM. Representative data are shown. (B, C, E, and F)
HAdV-5 or AdT* (FX binding-deﬁcient) (2  1010 vp/ml) was incubated for 30 min at 37°C with serum-free (SF) media or 90% Rag 2/ serum in the presence
or absence of X-bp (40 g/ml). Adenovirus suspensions were added to CHO-K1 (B), CHO-CAR (C), SKOV3 (E), or SKOV3-CAR (F) cells (MOI, 1,000 vp/cell) and
incubated at 37°C for 2 h. Then, the medium was replaced with media containing 2% FCS, and the cells were incubated for an additional 20 h. -Galactosidase
expression levels were quantiﬁed as relative light units (RLU) and normalized to the total milligrams of protein. The data represent pooled values from three
(B, C, and F) or four (E) independent experiments with four replicates per condition. Values are shown as a percentage of the SF-medium-alone condition and
expressed as the mean of the normalized values per experiment plus SEM. Transduction values (RLU/mg of total protein) for HAdV-5 in the presence of SF media
from a representative independent experiment are indicated below to add clarity on the magnitude of transduction levels: 4.8  104 (CHO-K1 cells), 3.8  106
(CHO-CAR cells). Repeated-measures ANOVA and posthoc Tukey’s range test were applied. *, P  0.05 versus matched controls; $, P  0.05 versus serum.
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The role of CAR in Rag 2/ serum-enhanced HAdV-5 transduction was conﬁrmed
using SKOV3 cells (CARlow) and SKOV3 cells engineered to stably express hCAR (SKOV3-
CAR) (Fig. 3D). Rag 2/ serum enhanced HAdV-5 transduction of SKOV3 cells by
approximately eightfold (Fig. 3E). Incubation of Rag 2/ serum with X-bp completely
inhibited the transduction-enhancing effects for HAdV-5 in SKOV3 cells (Fig. 3E),
supporting a predominant role for FX in mediating SKOV3 cell transduction for HAdV-5
in agreement with a previous report (18). Furthermore, Rag 2/ serum enhanced AdT*
transduction only minimally (Fig. 3E), again supporting the assertion that HAdV-5
transduction of SKOV3 cells in the presence of Rag 2/ serum is predominantly
mediated by FX. Rag 2/ serum also enhanced HAdV-5 transduction of SKOV3-CAR
cells (3.5-fold) (Fig. 3F). In contrast to SKOV3 cells, preincubation of Rag 2/ serum
with X-bp only marginally decreased Rag 2/ serum-enhanced HAdV-5 transduction
of SKOV3-CAR cells (Fig. 3F), indicating a minimal contribution of FX to serum-enhanced
HAdV-5 transduction in this cell line. Despite the lack of FX binding, transduction of
SKOV3-CAR cells with AdT* was enhanced threefold by Rag 2/ serum similar to that
for HAdV-5 (Fig. 3F). These data support the evidence for a FX-independent but
CAR-dependent mechanism of HAdV-5 transduction in the presence of immunocom-
promised mouse serum in CAR-expressing cells.
To further interrogate HAdV-5 receptor usage, soluble recombinant HAdV-5 ﬁber
knob (FK) or FK*, which contains the Y477A point mutation in the ﬁber DE loop to
prevent binding to CAR (30, 49, 50), was used. Binding of FK or FK* to CAR on the
plasma membrane was tested by performing competition assays for binding to CAR
with HAdV-5-EGFP (EGFP stands for enhanced green ﬂuorescent protein) or an anti-CAR
antibody. While preincubation of CHO-CAR cells with FK inhibited HAdV-5-EGFP bind-
ing to cells at a median inhibitory concentration (IC50) of 0.04 g/105 cells (Fig. 4A), FK*
did not reach IC50 even with excess levels of protein (100 g/105 cells) (Fig. 4B),
conﬁrming that FK* binding to CAR is substantially reduced. Similarly, incubation of
CHO-CAR cells with an anti-CAR antibody following preincubation of cells with FK
resulted in an IC50 of 0.017 g/105 cells (Fig. 4D). However, FK* failed to inhibit anti-CAR
antibody binding even at concentrations up to 100 g/105 cells (Fig. 4E), conﬁrming
the reduced FK* binding to CAR. In order to block CAR, A549 cells were incubated with
FK during HAdV-5 transduction in the presence of immunocompetent C57BL/6 serum
(Fig. 4C) or immunocompromised Rag 2/ (Fig. 4F) serum. FK* was used as a negative
control. C57BL/6 and Rag 2/ serum enhanced HAdV-5 transduction (Fig. 4C and F).
Preincubation of C57BL/6 serum with X-bp inhibited HAdV-5 transduction (Fig. 4C),
again supporting a role for FX binding HAdV-5 to protect it from neutralization. In
contrast, X-bp only marginally decreased Rag 2/ serum-enhanced transduction (Fig.
4F), as previously observed (Fig. 1A). Importantly, preincubation of cells with wild-type
FK but not FK* prevented both C57BL/6 and Rag 2/ serum-enhanced HAdV-5
transduction (Fig. 4C and F). These results indicate that blockade of CAR is sufﬁcient to
inhibit mouse serum-enhanced HAdV-5 transduction, supporting a role for CAR in
transduction in vitro in the presence of mouse serum.
A direct interaction with CAR is not necessary for HAdV-5 transduction in the
presence of immunocompromised mouse serum. Next, to assess whether HAdV-5
interaction with CAR in the presence of immunocompromised mouse serum is via a
direct interaction through the ﬁber knob domain, transduction assays in A549 cells
were performed in the presence of Rag 2/ serum using HAdV-5 KO1 (KO stands for
knockout). HAdV-5 KO1 has selective greatly reduced binding to CAR via point muta-
tions in speciﬁc residues within the ﬁber knob domain (S408E and P409A [29, 51]) to
maintain structural integrity of the capsid and avoid impairment of other possible
interactions that might take place with the HAdV-5 ﬁber. HAdV-5 KO1 transduction was
enhanced 2.8-fold in the presence of Rag 2/ serum, both with and without X-bp (Fig.
5A). These results indicate that the enhanced transduction observed in the presence of
mouse serum is FX independent and might not depend on direct interaction of HAdV-5
ﬁber knob with CAR.
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To conﬁrm that a direct interaction between HAdV-5 and CAR is not required in this
setting and that the mechanism behind mouse serum-enhanced transduction does not
involve a mouse serum protein(s) stabilizing the weak interaction of HAdV-5 KO1 ﬁber
knob with CAR, a HAdV-5 vector containing the ﬁber of CAR binding-deﬁcient HAdV-35
(HAdV-5/F35Luc [Luc stands for luciferase]) was used. HAdV-5/F35Luc transduction of
A549 cells was enhanced in the presence of Rag 2/ serum with and without X-bp
(Fig. 5B), indicating that transduction was FX independent and thus conﬁrming that
direct interaction between HAdV-5 and CAR is not required for Rag 2/ serum-
enhanced transduction.
The observation that a direct interaction between HAdV-5 and CAR is not necessary
for enhanced transduction in the presence of immunocompromised Rag 2/ serum
(Fig. 5A and B), together with the observation that addition of soluble FK directly to
cells did inhibit transduction (Fig. 4C and F), highlights the possibility that an additional
factor present in the serum may bridge HAdV-5 to CAR in this setting. Moreover, the
observation that HAdV-5/F35Luc transduction is enhanced by Rag 2/ serum in a
FX-independent manner suggests that the HAdV-5 ﬁber might be dispensable for
interactions with the mouse serum protein(s) required for HAdV-5 transduction in the
presence of mouse serum. To further investigate this hypothesis, soluble HAdV-5 ﬁber
was used. To conﬁrm that soluble ﬁber binding sites were functional, the ability of
soluble ﬁber to bind to CAR and block HAdV-5 transduction was conﬁrmed (Fig. 5C).
Next, transduction experiments with HAdV-5 on A549 cells were performed in the
FIG 4 Role of CAR on adenoviral transduction in the presence of mouse serum. (A, B, D, and E) Characterization of soluble recombinant ﬁber knob (FK) binding
to CAR. CHO-CAR cells were preincubated with FK or FK* (FK with a Y477A point mutation to impair binding to CAR) (0.0001 to 100 g/105 cells) at 4°C for
1 h to competitively inhibit HAdV-5-EGFP (A and B) or anti-CAR antibody (clone RmcB; Upstate, NY) (D and E) binding to CAR. FK-preincubated CHO-CAR cells
were incubated with HAdV-5-EGFP (10 PFU/cell) for 1 h at 4°C, the medium was replaced with media containing 10% FCS, the cells were incubated for an
additional 22 h at 37°C, and EGFP expression levels corresponding to transduced cells were quantiﬁed by ﬂow cytometry (A and B). FK-preincubated CHO-CAR
cells were incubated with anti-CAR antibody, and its binding was detected by ﬂow cytometry with Alexa Fluor 488-labeled goat anti-mouse IgG antibody (D
and E). (C and F) HAdV-5 (2  1010 vp/ml) was incubated for 30 min at 37°C with serum-free (SF) media, 90% C57BL/6 (C) or Rag 2/ (F) serum in the presence
or absence of X-bp (40 g/ml). Adenovirus suspensions were added to A549 cells (MOI, 1,000 vp/cell) that had been preincubated with SF media, soluble
recombinant ﬁber knob (FK), or FK* at 1 g/well. After 2 h of incubation at 37°C, the medium was replaced with 2% FCS-containing media, and the cells were
incubated for an additional 20 h. -Galactosidase expression levels were quantiﬁed as relative light units (RLU) and normalized to the total milligrams of protein.
There were three technical replicates per condition in panels A, B, D, and E. The pooled data from three independent experiments with four replicates per
condition are shown in panels C and F. Values are shown as a percentage of the SF-medium-alone condition and expressed as the mean of the normalized
values per experiment plus SEM. Repeated-measures ANOVA and posthoc Tukey’s range test were applied. *, P  0.05 versus matched controls; $, P  0.05
versus matched serum; #, P  0.05 versus serum plus FK*.
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presence of Rag 2/ serum that had been preincubated with X-bp and/or soluble
ﬁber. Rag 2/ serum preincubated with soluble ﬁber signiﬁcantly enhanced HAdV-5
transduction of A549 cells by 3.6-fold, and X-bp only marginally decreased the en-
hanced transduction, similar to that observed with untreated control Rag 2/ serum
(Fig. 5D). Importantly, preincubation of Rag 2/ serum with soluble ﬁber failed to
inhibit serum-enhanced HAdV-5 transduction in the presence of X-bp (Fig. 5D), pro-
viding further evidence that the HAdV-5 ﬁber might be dispensable for interactions
with the mouse serum protein(s) involved in HAdV-5 transduction in the presence of
mouse serum.
FVII, FIX, and PC are not required for HAdV-5 transduction in the presence of
mouse plasma. To investigate which circulating mouse blood protein(s) might be
FIG 5 Role of HAdV-5 ﬁber in adenovirus transduction in the presence of immunocompromised mouse serum. (A, B, and
D) HAdV-5, HAdV-5 KO1 (CAR binding greatly reduced), HAdV-5Luc, or HAdV-5/F35Luc (CAR binding-deﬁcient) (2  1010
vp/ml) was incubated for 30 min at 37°C with serum-free (SF) media or 90% Rag 2/ serum in the presence or absence
of X-bp (40 g/ml). When indicated, Rag 2/ serum was preincubated with soluble ﬁber (63.13 M) for 30 min at 37°C
before the addition of HAdV-5 (D). Adenovirus suspensions were added to A549 cells (MOI, 1,000 vp/cell) and incubated
at 37°C for 2 h. Then, the medium was replaced with media containing 2% FCS, and the cells were incubated for an
additional 20 h. (C) A549 cells were incubated with HAdV-5 (MOI, 10,000 vp/cell) at 37°C for 3 h following preincubation
of cells with serum-free (SF) media, soluble recombinant HAdV-5 ﬁber knob (FK), or FK* (Y477A point mutation to impair
binding to CAR) at 0.2 g/well or soluble HAdV-5 ﬁber at 0.59 g/well. The medium was replaced with 10% FCS-containing
media, and the cells were incubated for an additional 48 h. -Galactosidase (A, C, and D) or luciferase (B) expression levels
were quantiﬁed as relative light units (RLU) and normalized to the total milligrams of protein. Background chemilumi-
nescence was subtracted from all values in panel C. There were four technical replicates per condition (C) and pooled data
from four (A) or three (B and D) independent experiments with four replicates per condition. Values are shown as a
percentage of the SF-medium-alone condition and expressed as the mean of the normalized values per experiment plus
SEM (A, B, and D) or as the mean of values plus SEM (C). Repeated-measures ANOVA and posthoc Tukey’s range test were
applied. *, P  0.05 versus matched controls; $, P  0.05 versus serum; n.s, not signiﬁcant.
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involved in enhancing HAdV-5 transduction in vitro in the presence of mouse serum,
the ability of FVII, FIX, FX, PC, or C4BP to enhance HAdV-5 transduction of A549 cells
was assessed. CARlow SKOV3 cells were used as a negative control. As expected, FX
enhanced HAdV-5 transduction of A549 cells (Fig. 6A) and SKOV3 cells (Fig. 6B). In
contrast, FVII, FIX, PC, and C4BP failed to enhance HAdV-5 transduction (Fig. 6A and B).
To further assess whether the circulating mouse blood protein(s) involved in mouse
serum-enhanced HAdV-5 transduction requires the presence of other factors present in
mouse serum to enhance adenovirus transduction, HAdV-5 transduction of A549 cells
was assessed in the presence of plasma from C57BL/6 mice pretreated with warfarin to
deplete vitamin K-dependent coagulation factors (9) and supplemented with FVII, FIX,
FX, or PC. Plasma from peanut oil-treated C57BL/6 was used as a control. Warfarin
treatment reduced plasma FX levels from physiological levels of 10.8 to 1.1 g/ml (Fig.
6C). As expected, plasma from control C57BL/6 mice signiﬁcantly enhanced HAdV-5
transduction of A549 cells (2.8-fold) and addition of X-bp substantially reduced HAdV-5
transduction compared to the control (Fig. 6C). Plasma from warfarin-treated C57BL/6
mice failed to enhance HAdV-5 transduction (Fig. 6C), which suggests that a vitamin
K-dependent coagulation factor(s) might be responsible for the observed mouse
plasma-enhanced HAdV-5 transduction. Addition of X-bp to warfarin-treated C57BL/6
plasma substantially inhibited HAdV-5 transduction (Fig. 6C). Of the tested coagulation
factors, only addition of FX to warfarin-treated C57BL/6 plasma rescued mouse plasma-
enhanced HAdV-5 transduction (Fig. 6C), indicating that FX is required for mouse
plasma-enhanced transduction in contrast to FVII, FIX, and PC.
FIG 6 Effect of FVII, FIX, FX, PC, and C4BP on HAdV-5 transduction in vitro. (A and B) HAdV-5 (2  1010 vp/ml) was incubated for 30
min at 37°C with serum-free (SF) media containing human FVII (0.5 g/ml), FIX (5 g/ml), FX (10 g/ml), PC (4 g/ml), or C4BP (200
g/ml). Adenovirus suspensions were added to A549 (A) or SKOV3 (B) cells (MOI, 10,000 vp/cell) and incubated at 37°C for 2 h. (C)
HAdV-5 (2  1010 vp/ml) was incubated for 30 min at 37°C with SF media or 90% plasma of peanut oil- or warfarin-treated C57BL/6
mice in the presence or absence of X-bp (40 g/ml) or plasma supplemented with human FVII (0.5 g/ml), FIX (5 g/ml), FX (10
g/ml), or PC (4 g/ml). Adenovirus suspensions were added to A549 cells (MOI, 1,000 vp/cell) and incubated at 37°C for 2 h. The
medium was then replaced with media containing 2% FCS, and the cells were incubated for an additional 20 h (A to C).
-Galactosidase expression levels were quantiﬁed as relative light units (RLU) and normalized to the total milligrams of protein. The
relative concentration of FX in plasma from peanut oil- or warfarin-treated C57BL/6 mice was quantiﬁed by an ELISA (C). The data
represent pooled values from three independent experiments with four replicates per condition. Values are shown as a percentage
of the SF-medium-alone condition and expressed as the mean of the normalized values per experiment plus SEM. Repeated-measures
ANOVA and posthoc Tukey’s range test were applied. *, P  0.05 versus SF-medium-alone condition.
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In this study, the interactions that take place between HAdV-5 and host cells in vitro
in the presence of immunocompetent or immunocompromised mouse serum were
investigated. Blockade of HAdV-5–FX interactions with X-bp or the use of a FX binding-
deﬁcient HAdV-5 (AdT*) demonstrated that when HAdV-5 is exposed to immunocom-
petent mouse serum, the use of FX as a protective “shield” from “immune attack” is
essential to allow adenoviral transduction, in agreement with previous ﬁndings (17–19).
However, the contribution of FX to HAdV-5 transduction in vitro in the presence of
immunocompromised mouse serum lacking the mediators for “immune attack” is
minimal. Instead, HAdV-5 seems to predominantly follow a FX-independent mechanism
to transduce cells. The use of two different strains of immunocompromised mice (Rag
2/ and NSG) showed that the FX-independent pathway of adenoviral transduction
after exposure to mouse serum might be conserved across mouse strains. Furthermore,
blockade of CAR with soluble recombinant HAdV-5 ﬁber knob and the use of CHO-CAR
cells and SKOV3 cells expressing hCAR showed that the alternative FX-independent
mechanism that mediates HAdV-5 transduction in vitro in the presence of mouse serum
is dependent on CAR. Transduction experiments performed with HAdV-5 KO1 or CAR
binding-deﬁcient HAdV-5/F35Luc in the presence of immunocompromised Rag 2/
serum showed that direct interaction of HAdV-5 with CAR is not required for HAdV-5
transduction in the presence of mouse serum. This suggests the existence of a factor(s)
present in Rag 2/ serum that might bridge HAdV-5 to CAR for enhancement of
cell transduction. Moreover, the use of HAdV-5/F35Luc together with the assess-
ment of HAdV-5 transduction following incubation of Rag 2/ serum with soluble
HAdV-5 ﬁber showed that the HAdV-5 ﬁber might be dispensable for the use of the
novel CAR-mediated pathway. Supplementation of vitamin K-dependent coagulation
factor-depleted mouse plasma with individual coagulation factors showed that FVII, FIX,
and PC are not required for HAdV-5 cell transduction via the novel CAR-mediated
pathway. Instead, assessment of HAdV-5 transduction in the presence of mouse serum
that had been heat treated suggested a role for a heat-labile factor(s) in this setting.
Further experiments using inhibitors for speciﬁc components of the complement
system or depleting serum of IgM antibodies would provide valuable information in
deﬁning the mechanism mediating HAdV-5 transduction in the presence of immuno-
competent C57BL/6 serum.
In gene therapy, it is essential that the gene transfer vector reaches the target organ
while avoiding the activation of immune responses and toxic side effects. Thus, when
administering adenoviral vectors intravenously, knowledge about adenoviral behavior
and its interactions with blood proteins is crucial. Adenoviruses are pathogens that can
cause a wide range of infections, such as conjunctivitis, tonsillitis, respiratory tract or ear
infections, and gastroenteritis. To ﬁght infections, the host organism has developed a
series of physical and chemical barriers as well as the immune system; a network of
molecules, cells, and organs working together to protect the organism against threats.
Despite the effectiveness of the immune system against pathogens, adenoviruses have
evolved to take advantage of some of the interactions that take place in the host
organism. An example is coagulation factor X, which binds to HAdV-5 in the blood-
stream and is thought to be used as a protective “shield” against the attack on the
capsid by the immune system (17–19). Simultaneously, HAdV-5 also exploits this
interaction with FX to engage with HSPG on the surface of cells allowing viral entry (9,
11, 13, 14). While HAdV-5 can use HSPGs as cell receptors for transduction in vitro in the
presence of FX (13, 20) and in vivo when administered through the vasculature (9),
other studies showed that HAdV-5 liver transduction in immunocompromised mice
lacking IgM antibodies or complement was not impaired by ablation of HAdV-5–FX
interaction (17). Also, recent studies using mice lacking HS report that HSPGs are
dispensable for HAdV-5 liver transduction (20). These studies suggest that adenovirus
might follow other cell entry pathways when the FX-mediated pathway is not available.
Evidence that CAR is mainly expressed on the basolateral side of the plasma
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membrane (52, 53), an area not accessible for nonreplicating adenoviruses, has histor-
ically brought into question the biological relevance of HAdV-5–CAR interactions
during cell entry. CAR is part of the immunoglobulin superfamily encoded by a highly
conserved gene that via alternative splicing can generate ﬁve alternative transcripts
corresponding to three soluble isoforms (54, 55) and two transmembrane isoforms
(CAREx7 and CAREx8) that differ in their carboxy terminus (56). CAREx7, the most
abundant isoform, localizes to the basolateral surface of polarized epithelia and is
involved in cell-cell adhesion (57). Interestingly, a recent study showed that the CAREx8
isoform localizes to the apical membrane (56). Importantly, the expression of apical CAR
is stimulated by the proinﬂammatory cytokine and neutrophil chemoattractant inter-
leukin 8 (IL-8) and was associated with promotion of adenovirus cell entry (58). These
reports together with the evidence for a CAR-dependent mechanism of HAdV-5 trans-
duction of cells in vitro following exposure of virions to mouse serum might begin to
unravel alternative transduction mechanisms deﬁning HAdV-5 liver tropism following
intravascular delivery.
Here, the use of SKOV3 cells expressing low levels of CAR conﬁrmed that when
access to CAR is limited, HAdV-5 may transduce cells via the FX-mediated pathway in
the presence of Rag 2/ serum. These results suggest that the use of either the
FX-dependent pathway or the novel CAR-mediated pathway for HAdV-5 transduction
in the presence of Rag 2/ serummay depend on the availability of the corresponding
receptors (CAR and HSPG). This observation is in agreement with previous studies
showing that other adenovirus serotypes such as HAdV-35 can use FX, although with
lower afﬁnity than that of HAdV-5 and that FX might compete with CD46 for binding
to HAdV-35 (59). Our data suggest that the FX-dependent pathway and the novel
CAR-mediated pathway for HAdV-5 transduction in vitro in the presence of immuno-
compromised Rag 2/ serum may be available simultaneously. Based on these data,
however, the CAR-mediated pathway is the predominant route HAdV-5 follows for
transduction of cells in vitro in this setting. It still remains unclear what the determining
factors are for the use of one pathway or the other pathway or if they inﬂuence each
other. For instance, the relative abundance of HSPGs or CAR on the plasma membrane
might affect which pathway is used (48). Also, the differential levels of expression of
HSPGs and CAR in different cell lines might have an impact on receptor usage and
account for the differences observed on HAdV-5 transduction between cell lines or
tissues. The afﬁnity of HAdV-5 for individual components of the transduction pathways
identiﬁed (e.g., receptors, bridging molecules, etc.) might also determine the route of
entry that HAdV-5 follows during cell transduction. For example, a previous report
indicated that differences in the afﬁnity of HAdV-5–hFX or HAdV-5–mFX complexes for
HSPGs affected their ability to enhance HAdV-5 transduction in cultured cells (48).
Nevertheless, despite the CAR amino acid sequence being highly conserved (6, 60),
mouse and human CAR might differ in their interactions with mouse serum proteins.
Thus, the use of mouse cells expressing mouse CAR in HAdV-5 transduction studies in
the presence of mouse serum would provide useful mechanistic data on the use of the
novel CAR-mediated pathway for HAdV-5 transduction.
Experiments using other translationally relevant animal models or human samples
are fundamental in investigating the mechanisms mediating adenovirus transduction
and their implications for the clinic. Interestingly, a recent study showed high variability
in the effect of human serum (with no preexisting neutralizing human IgG [hIgG]
antibodies) on HAdV-5 in vitro neutralization and transduction (19), which is in contrast
to data from mouse models, highlighting the limitations of studies in small animal
models. This study demonstrated a protective role for FX binding to HAdV-5 capsids
against adenovirus neutralization in 56% of human serum samples analyzed and of the
remaining 44% that did not neutralize HAdV-5 in the absence of FX binding, some
individual serum samples enhanced transduction in a completely FX-dependent man-
ner and others enhanced transduction in a partially FX-dependent manner (19). Further
studies assessing the effect of IgM-depleted human serum with no preexisting neu-
tralizing hIgG antibodies on FX binding-deﬁcient HAdV-5 vectors will provide valuable
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information to dissect the underlying mechanisms of adenovirus tropism in humans
following systemic delivery of vectors.
Taken together, the data suggest that HAdV-5 can make use of different host cell
receptors (such as HSPGs and CAR) by binding to bridging molecules present in mouse
serum (Fig. 7). Receptor availability and afﬁnity in individual cells may determine the
entry pathway followed. Our ﬁndings have implications for understanding HAdV-5–
host interactions and for the development of safer and more efﬁcient adenoviral gene
transfer vectors.
MATERIALS AND METHODS
Ethics statement. All animal experiments were approved by the University of Glasgow Animal
Procedures and Ethics Committee and performed under UK Home Ofﬁce license (PPL 60/4429) in strict
accordance with UK Home Ofﬁce guidelines. Animals were housed under controlled environmental
conditions at ambient temperature with 12-h light/dark cycles. Mice were fed standard chow, and water
was provided ad libitum.
Immortalized cell lines. Adherent HEK293 cells (human embryonic kidney; ATCC CRL-1573), HeLa
cells (human cervix adenocarcinoma; ATCC CCL-2), and HepG2 cells (human liver hepatocellular carci-
noma; ATCC HB-8065) were cultured in minimum essential medium (MEM) (GIBCO by Life Technologies)
supplemented with 100 U/ml penicillin and 100 g/ml streptomycin (GIBCO by Life Technologies), 10%
(vol/vol) fetal calf serum (FCS) (PAA Laboratories), 1 mM sodium pyruvate (Sigma-Aldrich, UK) and 2 mM
L-glutamine (Invitrogen by Life Technologies) at 37°C and 5% CO2. Adherent A549 cells (human lung
carcinoma; ATCC CCL-185), SKOV3 cells (human ovary adenocarcinoma; ATCC HTB-77), and SKOV3-CAR
cells (SKOV3 cells engineered to stably overexpress red ﬂuorescent protein [RFP]-tagged human cox-
sackievirus and adenovirus receptor [hCAR]) were grown in Roswell Park Memorial Institute medium
(RPMI 1640) (GIBCO by Life Technologies) supplemented with 100 U/ml penicillin, 100 g/ml strepto-
mycin, 10% (vol/vol) FCS, 1 mM sodium pyruvate, and 2 mM L-glutamine at 37°C 5% CO2. SKOV3-CAR cell
medium was also supplemented with Geneticin (Gibco) at 1,000 ng/l. Adherent CHO-K1 cells (Chinese
hamster ovary; ATCC CCL-61) and CHO-CAR cells (CHO cells transfected to stably express human CAR
[hCAR] [5] [a kind gift from George Santis, King’s College London School of Medicine, London, UK]) were
grown in Ham’s F-10 nutrient mixture medium (GIBCO by Life Technologies) containing 1 mM
L-glutamine and 1 mM sodium pyruvate supplemented with 100 U/ml penicillin, 100 g/ml streptomy-
cin, and 10% (vol/vol) FCS at 37°C 5% CO2. The stable cell line SKOV3-CAR was generated by transfecting
a plasmid containing a RFP-tagged hCAR construct (61) (a gift from George Santis, King’s College London
School of Medicine, London, UK) into SKOV3 cells as described previously (62), and cell clones were
selected with Geneticin at 1,000 ng/l.
Adenoviral vector construction. Genetic characteristics of all adenoviral vectors used are described
in Table 1. HAdV-5-EGFP has been previously described (63). HAdV-5HVR5*HVR7*E451Q (termed AdT*)
(12) has seven point mutations in hexon HVRs 5 and 7 to ablate binding to coagulation FX (T270P and
FIG 7 Schematic representation of the suggested model of HAdV-5 cell transduction in the presence of
mouse serum. HAdV-5 may use FX for protection against adenovirus neutralization in the presence of
immunocompetent mouse serum. In the absence of adenovirus neutralization and in the presence
of mouse serum, HAdV-5 may transduce host cells through a coagulation factor X (FX)-dependent
mechanism and use an unidentiﬁed blood protein for transduction of host cells via the coxsackievirus
and adenovirus receptor (CAR). HSPG, heparan sulfate proteoglycans; C1q, complement component 1q;
C3b, complement component 3b.
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E271G in hexon HVR 5 and I421G, T423N, E424S, L426Y, and E451Q in HVR 7). HAdV-5/F35Luc is a HAdV-5
vector containing the ﬁber of HAdV-35 (59), and HAdV-5Luc (59) and HAdV-5/F35Luc encode the ﬁreﬂy
luciferase reporter gene under the cytomegalovirus immediate early promoter (CMV-IEP). HAdV-5 KO1
was designed and generated based on the AdEasy E1/E3-deleted HAdV-5 adenoviral vector system
(Stratagene by Agilent Technologies). As with HAdV-5 and AdT*, HAdV-5 KO1 carries the Escherichia coli
lacZ reporter gene, which encodes the bacterial cytoplasmic -galactosidase, under the CMV-IEP in place
of the viral E1 early gene. HAdV-5 KO1 has two point mutations (S408E and P409A [49, 51]) in the AB loop
region of the ﬁber knob domain that greatly reduce binding to CAR. The ﬁber open reading frame (ORF)
containing the KO1 mutation was excised from pAdT*KO1, a plasmid containing the AdT* vector genome
(12) with a mutated ﬁber ORF sequence. Brieﬂy, pAdT*KO1 was generated by homologous recombina-
tion with a shuttle vector engineered to contain the S408E and P409A mutations. The ﬁber ORF from
pAdT*KO1 was excised and inserted between the SpeI and MfeI sites 5= and 3= to the ﬁber ORF of
pShuttle-KO1-AAA (Agilent Technologies), respectively, to create pShuttle-KO1. pAdEasy1 (Agilent Tech-
nologies) and pShuttle-CMV-LacZ (Agilent Technologies) that had been linearized with PmeI, were
subjected to homologous DNA recombination to generate pAdEasy1-CMV-LacZ. Then, pShuttle-KO1 was
used to introduce the ﬁber ORF containing the KO1 mutation (excised with AscI and PacI sites 5= and 3=
of the ﬁber ORF, respectively) into the pAdEasy1-CMV-LacZ (linearized with SpeI) by homologous DNA
recombination to generate pAdEasy1-CMV-LacZ-KO1 (HAdV-5 KO1 genome).
Adenoviral vector production. HAdV-5, AdT*, HAdV-5 KO1, HAdV-5Luc, and HAdV-5/F35Luc vectors
were propagated and puriﬁed as described previously (18, 62). HAdV-5-EGFP has been previously
described (63). Quality control of all adenoviral vectors was performed by sequencing of the hexon HVR
or ﬁber knob regions encoding the mutations (primers for hexon HVR 5/HVR 7 [5=-CTCAGTGGTACGAA
ACTGAA-3=], hexon HVR 7 [5=-CTATGTGGAATCAGGCTGTT-3=], and ﬁber knob AB loop KO1 mutation
[5=-AATGCACCAAACACAAATCC-3=]) after ampliﬁcation of speciﬁc sequences by PCR (primers for hexon-F
[F stands for forward] [5=-CCCGCTTTCCAAGATGGCTA-3=], hexon-R [R stands for reverse] [5=-GTTGGCGG
GTATAGGGTAGA-3=], ﬁber-F [5=-ACTGCCACTGGTAGCTTGGG-3=], and ﬁber-R [5=-TGGCCAGCTGGTTTAGG
ATG-3=]) using the BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems by Life Technolo-
gies). Capillary electrophoresis was performed in a 3730 DNA analyzer (Applied Biosystems by Thermo
Fisher Scientiﬁc) using 3730 data collection v3.0 software. Titer determination of viral particles (vp)/ml
was performed with the microbicinchoninic acid (BCA) protein assay (Pierce, Thermo Scientiﬁc, USA)
using the conversion factor 1 g protein  4  109 vp. The number of PFU/ml was calculated by
endpoint dilution assay (62). Adenoviral capsid composition and integrity of capsid structure were
conﬁrmed by silver staining (using a Thermo Scientiﬁc kit according to the manufacturer’s instructions).
The laser-based nanoparticle tracking analysis (NTA) by NanoSight was used to characterize the size of
adenoviral particles from pure preparations with NanoSight NTA v2.3 software.
Construction of soluble ﬁber knob expression vectors and recombinant protein puriﬁcation.
The soluble ﬁber knobwt (wt stands for wild type) expression vector construction has been described
before (63). The point mutation Y447A in the ﬁber DE loop to impair binding to CAR (30, 49, 50) was
introduced into pQE30-Knobwt vector by mutagenic PCR using primers MutY477A-F (Mut stands for
mutant) (5=-TTCCTGGACCCAGAAGCTTGGAACTTTAGAAAT-3=) and MutY477A-R (5=-ATTTCTAAAGTTCCAA
GCTTCTGGGTCCAGGAA-3=) as described previously (64). Sequences were veriﬁed by sequencing using
primers pQE-F (5=-CGGATAACAATTTCACACAG-3=) and pQE-R (5=-GTTCTGAGGTCATTACTGG-3=). Positive
clones were transformed into SG13009 (pREP4) chemically competent E. coli (Qiagen) for protein
expression as described previously (63), and His-tagged soluble recombinant ﬁber knobwt (FK) and ﬁber
knobY477A (FK*) were puriﬁed by afﬁnity chromatography as before (63).
Characterization of soluble ﬁber knob binding to CAR. In order to conﬁrm the presence or
absence of binding of FK or FK* to CAR, respectively, these proteins were used to compete with
HAdV-5-EGFP or primary mouse monoclonal anti-CAR antibody (clone RmcB; Upstate, NY) for binding to
CAR on the plasma membrane of CHO-CAR cells. Increasing concentrations of FK or FK* (0.0001 g/105
cells to 100 g/105 cells) were preincubated with 1  105 CHO-CAR cells for 1 h at 4°C as described
previously (64). Next, cells were incubated with HAdV-5-EGFP (10 PFU/cell) for 1 h at 4°C and washed with
phosphate-buffered saline (PBS), the medium was replaced with medium containing 10% FCS, and cells
were incubated for further 22 h at 37°C and 5% CO2. In a separate experiment, cells pretreated with FK
or FK* (0.0001 to 100 g/105 cells) were incubated with primary mouse monoclonal anti-CAR antibody
(10 g/ml), and binding was detected using Alexa Fluor 488-labeled goat anti-mouse IgG antibody (Life




Protein targeted for mutation:
region and domain mutated Genetic mutation(s)
HAdV-5 Native tropism None None
HAdV-5-EGFP Native tropism None None
HAdV-5Luc Native tropism None None
AdT* (HAdV-5HVR5*HVR7*E451Q) FX-binding deﬁciency Hexon: HVR 5 and 7 T270P and E271G on HVR 5 and I421G, T423N,
E424S, L426Y, and E451Q on HVR 7
HAdV-5 KO1 Greatly reduced CAR
binding
Fiber: AB loop region of the
ﬁber knob domain
S408E and P409A
HAdV-5/F35Luc CAR-binding deﬁciency Fiber Serotyping of HAdV-5 with HAdV-35 ﬁber
aHAdV-5, human adenoviral vector serotype 5; HVR, hypervariable region; FX, coagulation factor X; CAR, coxsackievirus and adenovirus receptor.
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Technologies by Thermo Fisher Scientiﬁc) at 16 g/ml as described in the section below. EGFP expression
levels corresponding to transduced cells or Alexa Fluor 488-positive cells were detected by ﬂow
cytometry as described previously (64). Inhibition is expressed as the percentage of EGFP-positive or
Alexa Fluor 488-positive cells treated with ﬁber knob relative to the ﬂuorescence detected from a ﬁber
knob-untreated control. Median inhibitory concentration (IC50) values were calculated by nonlinear
regression analysis on a dose-response curve using GraphPad Prism v3.03 (GraphPad Software, San
Diego, CA, USA).
Assessment of CAR expression levels by ﬂow cytometry. Expression levels of CAR on the cell
membrane were measured by ﬂow cytometry. Cultured cells were washed with Dulbecco’s calcium- and
magnesium-free PBS (DPBS), dissociated with citric saline and resuspended in ice-cold serum-free (SF)
media to a concentration of 4  106 cells/ml. A total of 2  105 cells were incubated with an equal
volume of primary mouse monoclonal anti-CAR antibody (clone RmcB; Upstate, NY) or mouse IgG isotype
control (both at 5 g/ml in ice-cold SF media) for 30 min at 4°C in triplicate. The cells were washed twice
with SF media, incubated with secondary antibody (Alexa Fluor 488-labeled goat anti-mouse IgG; Life
Technologies by Thermo Fisher Scientiﬁc) for 30 min at 4°C (4 g/ml in ice-cold SF media), washed twice
with SF media, and resuspended in 150 l of ice-cold SF media for analysis. A BD FACSCanto II ﬂow
cytometer and BD FACSDiva v6.1.3 software were used for analysis and FlowJo single cell analysis v10.1
software for graphical representation. Viable cells were gated on the basis of forward and side light
scatter proﬁles, with a minimum of 10,000 gated events analyzed per sample.
Adenoviral transduction assay in the presence of blood factors, soluble recombinant HAdV-5
FK, or soluble HAdV-5 ﬁber. A549 or SKOV3 cells were seeded at 1  104 cells/well on 96-well culture
plates and incubated overnight at 37°C and 5% CO2. Adenoviral vectors (2 1010 vp/ml) were incubated
for 30 min at 37°C with 50 l SF media containing human FVII (0.5 g/ml), FIX (5 g/ml), FX (10 g/ml),
PC (4 g/ml), or C4BP (200 g/ml) (Cambridge Bioscience, UK). The cells were washed with SF media,
adenovirus suspensions were diluted 20-fold in SF media, and 100-l portions of the adenovirus
suspensions were added to cells (multiplicity of infection [MOI] of 10,000 vp/cell) and incubated at 37°C
for 2 h. Then, medium was replaced with media containing 2% FCS, and the cells were incubated for
further 20 h, washed with DPBS, and lysed with 100 l reporter lysis buffer (Promega, USA). When
indicated, human coagulation FX (hFX) was preincubated at 56°C for 30 min in 50 l SF media prior to
addition of adenoviral vectors, adenovirus suspensions were diluted 200-fold in SF media, and cells were
incubated with an MOI of 1,000 vp/cell. For transduction assays to assess adenovirus binding to FX,
cultured cells were transduced with an MOI of 1,000 vp/cell of adenoviral vectors for 3 h at 37°C and 5%
CO2 in the presence or absence of hFX at a working concentration of 10 g/ml. After the 3 h of
incubation, medium was replaced with 10% FCS-containing media, and cells were incubated for an
additional 48 h prior to cell lysis. For HAdV-5 ﬁber knob or ﬁber competition assays, cells were incubated
for 30 min at 4°C with FK (0.2 g/well), FK* (0.2 g/well), or soluble HAdV-5 ﬁber (0.59 g/well) (kindly
provided by John H. McVey, University of Surrey, Guildford, Surrey, UK) in 50 l SF media prior to addition
of 10,000 vp/cell adenoviral vectors in an equal volume of SF media and incubation for 3 h at 37°C. After
the 3 h of incubation, medium was replaced with 10% FCS-containing media, and cells were incubated
for an additional 48 h prior to cell lysis. -Galactosidase expression levels were quantiﬁed by Galacto-
Light Plus -galactosidase reporter gene assay (Life Technologies by Thermo Fisher Scientiﬁc, UK). Values
were expressed as relative light units (RLU) and normalized to the total milligrams of protein, which were
determined using the BCA protein assay (Pierce, Thermo Scientiﬁc, USA).
Adenoviral transduction assay in the presence of mouse serum. Cells were seeded at 1  104
cells/well on 96-well culture plates and incubated overnight at 37°C and 5% CO2. Fresh serum from
C57BL/6 (Harlan Laboratories, UK), Rag 2/ [B6(Cg)-Rag2tm1.1Cgn/J], or NSG (NOD-scid-gamma [NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ]) mice was separated from whole blood by centrifugation at 5,000  g for 10 min
at 4°C after the formation of a clot in a BD capillary blood collection microtainer tube (Fisher Scientiﬁc,
UK) and stored at 4°C. When plasma was required, a BD capillary blood collection microtainer tube with
lithium heparin designed for plasma collection was used (Fisher Scientiﬁc, UK). Adenoviral vectors (2 
1010 vp/ml) were incubated for 30 min at 37°C with 50 l SF media, fresh mouse serum, or serum
preincubated with X-bp (40 g/ml) at room temperature for 10 min. X-bp is a molecule that binds to the
FX GLA domain, inhibiting its binding to HAdV-5 (42). Cells were washed with SF media, adenoviral
suspensions were diluted 200-fold in SF media, and 100-l portions of the adenoviral suspensions were
added to the cells (MOI of 1,000 vp/cell). The cells were incubated at 37°C and 5% CO2 for 2 h, medium
was replaced with 2% FCS-containing media, and cells were incubated for an additional 20 h prior to cell
lysis. -Galactosidase activity was quantiﬁed as described above, luciferase activity was measured using
the luciferase assay (Promega, UK), and values were normalized to the total milligrams of protein as
described above. When indicated, mouse serum was preincubated with soluble HAdV-5 ﬁber (63.13 M)
for 30 min at 37°C following addition of X-bp and prior to addition of adenoviral vectors or preincubated
at 56°C for 30 min to inhibit the complement system prior to addition of X-bp as described previously
(17). When mouse plasma was used, the relative concentration of FX in plasma from mice treated with
peanut oil or warfarin (9, 65) was quantiﬁed by an enzyme-linked immunosorbent assay (ELISA) as
previously described (18), and 90% plasma of peanut oil- or warfarin-treated mice was supplemented
with human FVII (0.5 g/ml), FIX (5 g/ml), FX (10 g/ml), or PC (4 g/ml) prior to addition of X-bp. For
soluble recombinant HAdV-5 ﬁber knob assays, cells were incubated for 30 min at 4°C with 1 g/well of
FK or FK* in 50 l of SF media prior to adenovirus addition, and 50-l portions of adenoviral suspensions
(diluted 100-fold in SF media) were added to cells (MOI of 1,000 vp/cell).
Statistical analysis. Unpaired Student’s t test or repeated-measures analysis of variance (ANOVA)
and Tukey’s range test for posthoc pairwise comparisons of groups were performed for signiﬁcance
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assessment using GraphPad Prism v5.0 (GraphPad Software, San Diego, CA, USA), as speciﬁed for
each analysis. A P value of 0.05 was considered statistically signiﬁcant. In vitro data are shown as
a percentage of one of the conditions (speciﬁed for each experiment) and expressed as the mean
of values or of the normalized values per experiment  standard error of the mean (SEM). Three or
more independent experiments were performed in quadruplicate for each condition unless other-
wise stated.
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